PRESS RELEASE
Notable and CicloMed Initiate Phase 1B/2A Clinical Trial of Fosciclopirox in Acute Myelogenous Leukemia Under Co-Development Agreement
Notable Will Leverage Its High-Fidelity Predictive Precision Medicines Platform With The Goal Of Assessing Patient Responsiveness To Fosciclopirox
